Literature DB >> 3572357

Inactivation of influenza B virus by normal guinea-pig serum.

F Yamamoto, K Maeno, S Shibata, M Iinuma, A Miyama, Y Kawamoto.   

Abstract

Normal guinea-pig serum (GPS) lacking detectable antiviral antibody efficiently neutralized the infectivity of influenza B virus grown in chick embryos or MDCK cells. The inhibitor was heat-labile and sensitive to trypsin digestion. This beta-like inhibitor required Ca2+ and the complement components C1 and C4 for its activity. In contrast, GPS did not inactivate influenza A virus. Influenza B virus from which the neuraminidase activity of the spikes on the viral envelope had been eliminated by trypsin digestion was also inactivated to a level comparable to untreated virus. Complement component C1 alone bound directly to influenza B virus and inhibited its haemagglutinin activity. We suggest that the beta-like inhibitor in GPS is a component of the classical complement pathway which is triggered by the protein moiety of influenza B virus haemagglutinin, leading to virus neutralization.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3572357     DOI: 10.1099/0022-1317-68-4-1135

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

1.  Analysis of the mechanism of influenza B virus inactivation by guinea pig serum.

Authors:  F Yamamoto Goshima; K Maeno; S Shibata; H Mano; T Suzuki; Y Nishi
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

2.  Changes in the hemagglutinin gene of the neurovirulent influenza virus strain A/NWS/33.

Authors:  A C Ward; T F de Koning-Ward
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

3.  Bovine and mouse serum beta inhibitors of influenza A viruses are mannose-binding lectins.

Authors:  E M Anders; C A Hartley; D C Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

Review 4.  In the Crosshairs: RNA Viruses OR Complement?

Authors:  Nisha Asok Kumar; Umerali Kunnakkadan; Sabu Thomas; John Bernet Johnson
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.